Valeant Ex-Execs Under Probe; Stocks Fall

Nov 01, 2016

Bloomberg

United States prosecutors are targeting Valeant Pharmaceuticals' former CEO J. Michael Pearson and CFO Howard Schiller as they build a potential accounting fraud case against the company. Sources say charges could be filed within weeks, according to a Bloomberg article.

The accounting fraud charges are related to the company’s hidden ties to Philidor Rx Services LLC, a specialty pharmacy company that Valeant secretly controlled, the article said. Federal prosecutors and FBI agents in New York have been investigating the company for at least a year, the story said.

Read the Bloomberg article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments